Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM

Inclusion Criteria:

1. Age ≥ 18 years
2. No gender restriction
3. Pathologically or clinically diagnosed with colorectal liver metastases
4. Imaging data available within 31 days prior to enrollment, with at least one measurable lesion (according to RECIST criteria)
5. Patients received only DEB-TACE combined with HAIC or HAIC alone during the observation period
6. Child-Pugh classification A or B
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

Exclusion Criteria:

1. Presence of treatment risks or contraindications to DEB-TACE combined with HAIC or HAIC alone.
2. Concurrent diagnosis of other malignancies.
3. Underwent other local treatment modalities during the observation period.
4. DEB-TACE combined with HAIC or HAIC alone was used as postoperative adjuvant therapy.
5. Missing relevant examination results before or after treatment.
6. Incomplete imaging data, making response evaluation impossible.
7. Follow-up failure due to incorrect or missing patient information, loss to follow-up, or patient refusal.

   \-